# Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix

> **NCT00285207** · PHASE2 · COMPLETED · sponsor: **Tigris Pharmaceuticals** · enrollment: 147 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Uterine Cervical Dysplasia

## Interventions

- **DRUG:** placebo
- **DRUG:** A007

## Key facts

- **NCT ID:** NCT00285207
- **Lead sponsor:** Tigris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-01
- **Primary completion:** 2008-04
- **Final completion:** 2008-06
- **Target enrollment:** 147 (ACTUAL)
- **Last updated:** 2010-10-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00285207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00285207, "Safety and Efficacy of A-007 Topical Gel in the Treatment of High-Grade Squamous Intraepithelial Lesions (HSIL) of the Cervix". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00285207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*